AU731705B2 - Liposomal influenza vaccine composition and method - Google Patents
Liposomal influenza vaccine composition and method Download PDFInfo
- Publication number
- AU731705B2 AU731705B2 AU31882/97A AU3188297A AU731705B2 AU 731705 B2 AU731705 B2 AU 731705B2 AU 31882/97 A AU31882/97 A AU 31882/97A AU 3188297 A AU3188297 A AU 3188297A AU 731705 B2 AU731705 B2 AU 731705B2
- Authority
- AU
- Australia
- Prior art keywords
- composition
- liposomes
- cytokine
- liposomal
- csf
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 238000000034 method Methods 0.000 title claims abstract description 26
- 239000000203 mixture Substances 0.000 title claims description 69
- 229960003971 influenza vaccine Drugs 0.000 title abstract description 9
- 102000004127 Cytokines Human genes 0.000 claims abstract description 67
- 108090000695 Cytokines Proteins 0.000 claims abstract description 67
- 239000000427 antigen Substances 0.000 claims abstract description 60
- 108091007433 antigens Proteins 0.000 claims abstract description 60
- 102000036639 antigens Human genes 0.000 claims abstract description 60
- 239000002502 liposome Substances 0.000 claims abstract description 58
- 229960005486 vaccine Drugs 0.000 claims abstract description 39
- 230000003053 immunization Effects 0.000 claims abstract description 20
- 206010022000 influenza Diseases 0.000 claims abstract description 14
- 108010002350 Interleukin-2 Proteins 0.000 claims description 63
- 102000000588 Interleukin-2 Human genes 0.000 claims description 63
- 150000002632 lipids Chemical class 0.000 claims description 29
- 239000002202 Polyethylene glycol Substances 0.000 claims description 15
- 229920001223 polyethylene glycol Polymers 0.000 claims description 15
- 241000712461 unidentified influenza virus Species 0.000 claims description 12
- 238000007912 intraperitoneal administration Methods 0.000 claims description 11
- 230000028993 immune response Effects 0.000 claims description 8
- 238000007918 intramuscular administration Methods 0.000 claims description 8
- 239000002691 unilamellar liposome Substances 0.000 claims description 7
- 230000003308 immunostimulating effect Effects 0.000 claims description 6
- 238000001990 intravenous administration Methods 0.000 claims description 6
- 238000007920 subcutaneous administration Methods 0.000 claims description 6
- 239000000725 suspension Substances 0.000 claims description 6
- CITHEXJVPOWHKC-UUWRZZSWSA-N 1,2-di-O-myristoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCC CITHEXJVPOWHKC-UUWRZZSWSA-N 0.000 claims description 5
- 108010052285 Membrane Proteins Proteins 0.000 claims description 5
- 102000005348 Neuraminidase Human genes 0.000 claims description 5
- 108010006232 Neuraminidase Proteins 0.000 claims description 5
- 230000000890 antigenic effect Effects 0.000 claims description 4
- 229960003724 dimyristoylphosphatidylcholine Drugs 0.000 claims description 4
- 230000003612 virological effect Effects 0.000 claims description 4
- 108010002586 Interleukin-7 Proteins 0.000 claims description 3
- 102000018697 Membrane Proteins Human genes 0.000 claims description 3
- 210000003714 granulocyte Anatomy 0.000 claims description 3
- 208000015181 infectious disease Diseases 0.000 claims description 3
- 108010065805 Interleukin-12 Proteins 0.000 claims description 2
- 108090000978 Interleukin-4 Proteins 0.000 claims description 2
- 108090001005 Interleukin-6 Proteins 0.000 claims description 2
- 210000002540 macrophage Anatomy 0.000 claims description 2
- 238000011160 research Methods 0.000 claims description 2
- 108010002352 Interleukin-1 Proteins 0.000 claims 1
- 108090000172 Interleukin-15 Proteins 0.000 claims 1
- 240000007594 Oryza sativa Species 0.000 claims 1
- 235000007164 Oryza sativa Nutrition 0.000 claims 1
- 235000009566 rice Nutrition 0.000 claims 1
- 230000004936 stimulating effect Effects 0.000 claims 1
- 230000004044 response Effects 0.000 abstract description 33
- 238000002649 immunization Methods 0.000 abstract description 18
- 230000000091 immunopotentiator Effects 0.000 abstract description 2
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 50
- 241000699670 Mus sp. Species 0.000 description 46
- 238000002360 preparation method Methods 0.000 description 18
- 238000002255 vaccination Methods 0.000 description 18
- 241000700605 Viruses Species 0.000 description 17
- 210000004027 cell Anatomy 0.000 description 17
- 210000002966 serum Anatomy 0.000 description 17
- 238000012360 testing method Methods 0.000 description 15
- 238000011725 BALB/c mouse Methods 0.000 description 14
- 238000002965 ELISA Methods 0.000 description 13
- 239000003795 chemical substances by application Substances 0.000 description 11
- 230000000694 effects Effects 0.000 description 11
- 238000003556 assay Methods 0.000 description 10
- 238000005538 encapsulation Methods 0.000 description 10
- 210000004988 splenocyte Anatomy 0.000 description 10
- 230000003013 cytotoxicity Effects 0.000 description 9
- 231100000135 cytotoxicity Toxicity 0.000 description 9
- 230000007774 longterm Effects 0.000 description 9
- 102000004169 proteins and genes Human genes 0.000 description 9
- 108090000623 proteins and genes Proteins 0.000 description 9
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 description 6
- 241000252870 H3N2 subtype Species 0.000 description 6
- -1 ML-6 Proteins 0.000 description 6
- 230000005875 antibody response Effects 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 229940031626 subunit vaccine Drugs 0.000 description 6
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 5
- 238000011260 co-administration Methods 0.000 description 5
- 230000001472 cytotoxic effect Effects 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 210000004072 lung Anatomy 0.000 description 5
- 150000008104 phosphatidylethanolamines Chemical class 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 4
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 4
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 4
- 239000004322 Butylated hydroxytoluene Substances 0.000 description 4
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 4
- 239000012981 Hank's balanced salt solution Substances 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- QPCDCPDFJACHGM-UHFFFAOYSA-N N,N-bis{2-[bis(carboxymethyl)amino]ethyl}glycine Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(=O)O)CCN(CC(O)=O)CC(O)=O QPCDCPDFJACHGM-UHFFFAOYSA-N 0.000 description 4
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 4
- 210000001744 T-lymphocyte Anatomy 0.000 description 4
- 210000000612 antigen-presenting cell Anatomy 0.000 description 4
- 229940098773 bovine serum albumin Drugs 0.000 description 4
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- 230000028996 humoral immune response Effects 0.000 description 4
- 230000008348 humoral response Effects 0.000 description 4
- 230000002209 hydrophobic effect Effects 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 229960003330 pentetic acid Drugs 0.000 description 4
- 230000001681 protective effect Effects 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 238000003860 storage Methods 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 241000712431 Influenza A virus Species 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 102000011931 Nucleoproteins Human genes 0.000 description 3
- 108010061100 Nucleoproteins Proteins 0.000 description 3
- 229910019142 PO4 Inorganic materials 0.000 description 3
- 208000036142 Viral infection Diseases 0.000 description 3
- 229940037003 alum Drugs 0.000 description 3
- 239000012736 aqueous medium Substances 0.000 description 3
- 230000004071 biological effect Effects 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 230000007402 cytotoxic response Effects 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 230000002708 enhancing effect Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 208000037797 influenza A Diseases 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 239000002184 metal Substances 0.000 description 3
- 230000035772 mutation Effects 0.000 description 3
- 230000001338 necrotic effect Effects 0.000 description 3
- 238000006386 neutralization reaction Methods 0.000 description 3
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 3
- 239000010452 phosphate Substances 0.000 description 3
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 3
- 150000003904 phospholipids Chemical class 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 230000009385 viral infection Effects 0.000 description 3
- 101710145634 Antigen 1 Proteins 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 102000007644 Colony-Stimulating Factors Human genes 0.000 description 2
- 108010071942 Colony-Stimulating Factors Proteins 0.000 description 2
- 102000020897 Formins Human genes 0.000 description 2
- 108091022623 Formins Proteins 0.000 description 2
- 102000003886 Glycoproteins Human genes 0.000 description 2
- 108090000288 Glycoproteins Proteins 0.000 description 2
- 239000000232 Lipid Bilayer Substances 0.000 description 2
- 102000007651 Macrophage Colony-Stimulating Factor Human genes 0.000 description 2
- 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 101710141454 Nucleoprotein Proteins 0.000 description 2
- 102400000368 Surface protein Human genes 0.000 description 2
- 229930003427 Vitamin E Natural products 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000000840 anti-viral effect Effects 0.000 description 2
- 239000007900 aqueous suspension Substances 0.000 description 2
- 230000003190 augmentative effect Effects 0.000 description 2
- 210000003719 b-lymphocyte Anatomy 0.000 description 2
- 238000004166 bioassay Methods 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000002738 chelating agent Substances 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 210000004443 dendritic cell Anatomy 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 239000012636 effector Substances 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 238000001125 extrusion Methods 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 2
- 238000000265 homogenisation Methods 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 230000002045 lasting effect Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000035800 maturation Effects 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- 239000001294 propane Substances 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 210000004989 spleen cell Anatomy 0.000 description 2
- MLGCXEBRWGEOQX-UHFFFAOYSA-N tetradifon Chemical compound C1=CC(Cl)=CC=C1S(=O)(=O)C1=CC(Cl)=C(Cl)C=C1Cl MLGCXEBRWGEOQX-UHFFFAOYSA-N 0.000 description 2
- 235000019165 vitamin E Nutrition 0.000 description 2
- 229940046009 vitamin E Drugs 0.000 description 2
- 239000011709 vitamin E Substances 0.000 description 2
- 229910018626 Al(OH) Inorganic materials 0.000 description 1
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 1
- 241001227713 Chiron Species 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 229930186217 Glycolipid Natural products 0.000 description 1
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 description 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 1
- 101001002657 Homo sapiens Interleukin-2 Proteins 0.000 description 1
- 241000134304 Influenza A virus H3N2 Species 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 231100000002 MTT assay Toxicity 0.000 description 1
- 238000000134 MTT assay Methods 0.000 description 1
- 101710085938 Matrix protein Proteins 0.000 description 1
- 101710127721 Membrane protein Proteins 0.000 description 1
- 101710169105 Minor spike protein Proteins 0.000 description 1
- 101710081079 Minor spike protein H Proteins 0.000 description 1
- 101000746384 Mus musculus Granulocyte colony-stimulating factor Proteins 0.000 description 1
- UBQYURCVBFRUQT-UHFFFAOYSA-N N-benzoyl-Ferrioxamine B Chemical compound CC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCN UBQYURCVBFRUQT-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 241000158500 Platanus racemosa Species 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 230000027645 antigenic variation Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- 239000003012 bilayer membrane Substances 0.000 description 1
- 238000001815 biotherapy Methods 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 229940095259 butylated hydroxytoluene Drugs 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 229930183167 cerebroside Natural products 0.000 description 1
- 150000001784 cerebrosides Chemical class 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 229940028617 conventional vaccine Drugs 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 229940099217 desferal Drugs 0.000 description 1
- 238000011026 diafiltration Methods 0.000 description 1
- BPHQZTVXXXJVHI-UHFFFAOYSA-N dimyristoyl phosphatidylglycerol Chemical compound CCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCCCCCCCC BPHQZTVXXXJVHI-UHFFFAOYSA-N 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000012154 double-distilled water Substances 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 230000000763 evoking effect Effects 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 125000002485 formyl group Chemical class [H]C(*)=O 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 150000002270 gangliosides Chemical class 0.000 description 1
- 230000035931 haemagglutination Effects 0.000 description 1
- 210000002443 helper t lymphocyte Anatomy 0.000 description 1
- 102000055277 human IL2 Human genes 0.000 description 1
- 150000002430 hydrocarbons Chemical group 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 229960000367 inositol Drugs 0.000 description 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 231100001231 less toxic Toxicity 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229940124590 live attenuated vaccine Drugs 0.000 description 1
- 229940023012 live-attenuated vaccine Drugs 0.000 description 1
- 239000008176 lyophilized powder Substances 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 210000004779 membrane envelope Anatomy 0.000 description 1
- ZAHQPTJLOCWVPG-UHFFFAOYSA-N mitoxantrone dihydrochloride Chemical compound Cl.Cl.O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO ZAHQPTJLOCWVPG-UHFFFAOYSA-N 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000002808 molecular sieve Substances 0.000 description 1
- 210000000066 myeloid cell Anatomy 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 125000005539 phosphatidic acid group Chemical group 0.000 description 1
- 239000004417 polycarbonate Substances 0.000 description 1
- 229920000515 polycarbonate Polymers 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000004513 sizing Methods 0.000 description 1
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 1
- RWVGQQGBQSJDQV-UHFFFAOYSA-M sodium;3-[[4-[(e)-[4-(4-ethoxyanilino)phenyl]-[4-[ethyl-[(3-sulfonatophenyl)methyl]azaniumylidene]-2-methylcyclohexa-2,5-dien-1-ylidene]methyl]-n-ethyl-3-methylanilino]methyl]benzenesulfonate Chemical compound [Na+].C1=CC(OCC)=CC=C1NC1=CC=C(C(=C2C(=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C)C=2C(=CC(=CC=2)N(CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C)C=C1 RWVGQQGBQSJDQV-UHFFFAOYSA-M 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 125000002345 steroid group Chemical group 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 239000010409 thin film Substances 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
- 238000003260 vortexing Methods 0.000 description 1
- 239000007762 w/o emulsion Substances 0.000 description 1
- 210000000707 wrist Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/145—Orthomyxoviridae, e.g. influenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55522—Cytokines; Lymphokines; Interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55522—Cytokines; Lymphokines; Interferons
- A61K2039/55527—Interleukins
- A61K2039/55533—IL-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S436/00—Chemistry: analytical and immunological testing
- Y10S436/829—Liposomes, e.g. encapsulation
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pulmonology (AREA)
- Oncology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US2006396P | 1996-06-24 | 1996-06-24 | |
| US60/020063 | 1996-06-24 | ||
| PCT/IL1997/000210 WO1997049423A2 (en) | 1996-06-24 | 1997-06-24 | Liposomal influenza vaccine composition and method |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU3188297A AU3188297A (en) | 1998-01-14 |
| AU731705B2 true AU731705B2 (en) | 2001-04-05 |
Family
ID=21796541
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU31882/97A Ceased AU731705B2 (en) | 1996-06-24 | 1997-06-24 | Liposomal influenza vaccine composition and method |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US5919480A (cg-RX-API-DMAC10.html) |
| EP (1) | EP0954286B1 (cg-RX-API-DMAC10.html) |
| JP (2) | JP4227195B2 (cg-RX-API-DMAC10.html) |
| AT (1) | ATE422352T1 (cg-RX-API-DMAC10.html) |
| AU (1) | AU731705B2 (cg-RX-API-DMAC10.html) |
| CA (1) | CA2258878C (cg-RX-API-DMAC10.html) |
| DE (1) | DE69739253D1 (cg-RX-API-DMAC10.html) |
| WO (1) | WO1997049423A2 (cg-RX-API-DMAC10.html) |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7731972B1 (en) * | 2000-02-04 | 2010-06-08 | Vlaams Interuniversitair Instituut Voor Biotechnologie | Immunoprotective influenza antigen and its use in vaccination |
| EP1027071A2 (en) * | 1997-10-31 | 2000-08-16 | Cistron Biotechnology Inc. | Encapsulated immunomodulators useful as vaccine adjuvants |
| AT407958B (de) * | 1999-02-11 | 2001-07-25 | Immuno Ag | Inaktivierte influenza-virus-vakzine zur nasalen oder oralen applikation |
| CA2428103C (en) | 2000-11-07 | 2015-06-09 | Immunovaccine Technologies Inc. | Vaccines with enhanced immune response and methods for their preparation |
| WO2002040504A2 (en) * | 2000-11-15 | 2002-05-23 | The Government Of The United States Of America, Represnted By The Secretary, Department Of Health And Human Services | Sol-fusin: use of gp64-6his to catalyze membrane fusion |
| TWI228420B (en) * | 2001-05-30 | 2005-03-01 | Smithkline Beecham Pharma Gmbh | Novel vaccine composition |
| EP1404298A2 (en) * | 2001-06-25 | 2004-04-07 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | A method for preparation of vesicles loaded with biological material and different uses thereof |
| ATE431745T1 (de) * | 2001-07-05 | 2009-06-15 | Ltb4 Sweden Ab | Ltb4 als adjuvans für impfstoffe |
| CN1665487A (zh) * | 2002-07-03 | 2005-09-07 | 埃弗顿有限公司 | 脂质体疫苗 |
| US20040247661A1 (en) * | 2002-07-03 | 2004-12-09 | Dov Michaeli | Liposomal vaccine |
| US20050169979A1 (en) * | 2002-07-03 | 2005-08-04 | Dov Michaeli | Liposomal vaccine |
| US9028863B2 (en) | 2003-04-25 | 2015-05-12 | The Penn State Research Foundation | Method and system for systemic delivery of growth arresting, lipid-derived bioactive compounds |
| US20060286161A1 (en) * | 2003-05-09 | 2006-12-21 | Steffen Panzner | Injectable liposomal depots for delivering active ingredients |
| RU2390351C2 (ru) * | 2003-08-11 | 2010-05-27 | Дзе Ресерч Фаундейшн Фо Макробайал Дизизес Оф Осака Юниверсити | Вакцина против вируса гриппа для введения через слизистую и способ предотвращения гриппа |
| CN1893925B (zh) * | 2003-08-21 | 2011-04-27 | 利普泰克有限公司 | 树突细胞的体内靶向 |
| FR2868951B1 (fr) * | 2004-04-15 | 2006-07-21 | Ethypharm Sa | Compositions contenant ds vesicules lamellaires incorporant un principe actif peu soluble dans l'eau et produits intermediaires utiles pour leur preparation |
| US20050260260A1 (en) * | 2004-05-19 | 2005-11-24 | Edward Kisak | Liposome compositions for the delivery of macromolecules |
| JP2008526870A (ja) * | 2005-01-05 | 2008-07-24 | フイラデルフイア・ヘルス・アンド・エデユケーシヨン・コーポレーシヨン | 送達ビヒクル、生体作用活性物質およびウイルスワクチン |
| CA2523032A1 (en) | 2005-10-07 | 2007-04-07 | Immunovaccine Technologies Inc. | Vaccines for cancer therapy |
| AU2008303023B2 (en) | 2007-09-27 | 2014-01-09 | Immunovaccine Technologies Inc. | Use of liposomes in a carrier comprising a continuous hydrophobic phase for delivery of polynucleotides in vivo |
| US20100209452A1 (en) * | 2007-10-03 | 2010-08-19 | Immunovaccine Technologies, Inc | Compositions comprising an antigen, an amphipathic compound and a hydrophobic carrier, and uses thereof |
| WO2009090650A2 (en) * | 2008-01-16 | 2009-07-23 | Ben-Gurion University Of The Negev Research And Development Authority | Vaccine for alzheimer's disease |
| US20110070298A1 (en) | 2008-06-05 | 2011-03-24 | Immunovaccine Technologies Inc. | Compositions Comprising Liposomes, An Antigen, A Polynucleotide and A Carrier Comprising a Continuous Phase of a Hydrophobic Substance |
| JP5681626B2 (ja) | 2008-07-14 | 2015-03-11 | ポリーペイド リミテッドＰｏｌｙｐｉｄ Ｌｔｄ． | 徐放性薬剤キャリア組成物 |
| EP2391370B1 (en) | 2009-02-02 | 2015-06-03 | Galmed Research and Development Ltd. | Methods and compositions for treating alzheimer's disease |
| CA2803282C (en) | 2009-07-06 | 2018-05-01 | David E. Anderson | Methods for preparing vesicles and formulations produced therefrom |
| EP2451950B9 (en) | 2009-07-06 | 2016-11-23 | Variation Biotechnologies Inc. | Methods for preparing vesicles and formulations produced therefrom |
| US8992979B2 (en) | 2009-07-14 | 2015-03-31 | Polypid Ltd. | Sustained-release drug carrier composition |
| CA2775564A1 (en) * | 2009-10-09 | 2011-04-14 | New York Blood Center, Inc. | Immunopotentiator-linked oligomeric influenza immunogenic compositions |
| CN102892406B (zh) | 2010-01-19 | 2015-04-08 | 波利皮得有限公司 | 缓释核酸基质组合物 |
| JP6119030B2 (ja) * | 2010-07-06 | 2017-04-26 | ヴァリエーション バイオテクノロジーズ インコーポレイテッド | インフルエンザを治療するための組成物及び方法 |
| BR112013018074A2 (pt) | 2011-01-13 | 2020-12-01 | Variation Biotechnologies, Inc. | métodos para a preparação de vesículas e formulações produzidas a partir dessas |
| BR112013017939B1 (pt) | 2011-01-13 | 2022-11-16 | Variation Biotechnologies Inc | Composição imunogênica liofilizada termoestável, uso e método para preparação da mesma |
| US10105435B2 (en) | 2011-10-06 | 2018-10-23 | Immunovaccine Technologies Inc. | Liposome compositions comprising an adjuvant that activates or increases the activity of TLR2 and uses thereof |
| CA2890084C (en) | 2011-11-18 | 2021-05-04 | Maura Ellen Campbell | Synthetic derivatives of mpl and uses thereof |
| CA2894442C (en) | 2012-01-12 | 2020-01-21 | Variation Biotechnologies Inc. | Compositions and methods for treating viral infections |
| CA2894467A1 (en) | 2012-01-27 | 2013-08-01 | Variation Biotechnologies Inc. | Methods for preparing thermostable compositions comprising a lipid component and thermolabile therapeutic agents |
| CN103736090B (zh) * | 2014-01-27 | 2016-03-02 | 中国医学科学院医学生物学研究所 | 甲磺酸去铁胺佐剂及含甲磺酸去铁胺佐剂的疫苗 |
| CN110151702A (zh) * | 2019-06-24 | 2019-08-23 | 昆明医科大学 | 聚乙二醇修饰流感疫苗脂质体及其制备方法 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0356339A1 (en) * | 1988-08-25 | 1990-02-28 | The Liposome Company, Inc. | Influenza vaccine and novel adjuvants |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4117113A (en) * | 1974-06-25 | 1978-09-26 | National Research Development Corporation | Immunological preparations |
| US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
| US4235877A (en) * | 1979-06-27 | 1980-11-25 | Merck & Co., Inc. | Liposome particle containing viral or bacterial antigenic subunit |
| US4426330A (en) | 1981-07-20 | 1984-01-17 | Lipid Specialties, Inc. | Synthetic phospholipid compounds |
| US4534899A (en) | 1981-07-20 | 1985-08-13 | Lipid Specialties, Inc. | Synthetic phospholipid compounds |
| JPH0720857B2 (ja) * | 1988-08-11 | 1995-03-08 | テルモ株式会社 | リポソームおよびその製法 |
| US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| JP3037994B2 (ja) * | 1989-11-02 | 2000-05-08 | テルモ株式会社 | リポソーム表面への蛋白質吸着抑制剤 |
| JP3220180B2 (ja) * | 1991-05-23 | 2001-10-22 | 三菱化学株式会社 | 薬剤含有タンパク質結合リポソーム |
| ZA934890B (en) * | 1992-07-08 | 1994-04-14 | Schering Corp | Use of Gm-CSF as a vaccine adjuvant |
| US6326353B1 (en) * | 1993-03-23 | 2001-12-04 | Sequus Pharmaceuticals, Inc. | Enhanced circulation effector composition and method |
| ATE179599T1 (de) * | 1993-08-06 | 1999-05-15 | Opperbas Holding Bv | Verfahren zur hohen beladung von vesikeln mit biopolymeren substanzen |
| AUPM500494A0 (en) * | 1994-04-12 | 1994-05-05 | Minister For Agriculture & Rural Affairs For The State Of New South Wales, The | Composition for use in increasing mucosal immunity |
-
1997
- 1997-06-23 US US08/880,238 patent/US5919480A/en not_active Expired - Lifetime
- 1997-06-24 CA CA002258878A patent/CA2258878C/en not_active Expired - Fee Related
- 1997-06-24 WO PCT/IL1997/000210 patent/WO1997049423A2/en not_active Ceased
- 1997-06-24 AU AU31882/97A patent/AU731705B2/en not_active Ceased
- 1997-06-24 EP EP97927355A patent/EP0954286B1/en not_active Expired - Lifetime
- 1997-06-24 JP JP50263298A patent/JP4227195B2/ja not_active Expired - Fee Related
- 1997-06-24 DE DE69739253T patent/DE69739253D1/de not_active Expired - Lifetime
- 1997-06-24 AT AT97927355T patent/ATE422352T1/de not_active IP Right Cessation
-
2008
- 2008-06-06 JP JP2008149959A patent/JP2008260779A/ja not_active Withdrawn
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0356339A1 (en) * | 1988-08-25 | 1990-02-28 | The Liposome Company, Inc. | Influenza vaccine and novel adjuvants |
| EP0626169A2 (en) * | 1988-08-25 | 1994-11-30 | The Liposome Company, Inc. | A dosage form comprising an antigen and a salt form of an organic acid derivative of a sterol |
Also Published As
| Publication number | Publication date |
|---|---|
| DE69739253D1 (de) | 2009-03-26 |
| US5919480A (en) | 1999-07-06 |
| CA2258878A1 (en) | 1997-12-31 |
| EP0954286B1 (en) | 2009-02-11 |
| ATE422352T1 (de) | 2009-02-15 |
| CA2258878C (en) | 2008-03-18 |
| JP2000513352A (ja) | 2000-10-10 |
| EP0954286A2 (en) | 1999-11-10 |
| WO1997049423A2 (en) | 1997-12-31 |
| JP4227195B2 (ja) | 2009-02-18 |
| JP2008260779A (ja) | 2008-10-30 |
| WO1997049423A3 (en) | 1998-02-19 |
| AU3188297A (en) | 1998-01-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU731705B2 (en) | Liposomal influenza vaccine composition and method | |
| CA2086831C (en) | Immunostimulating and immunopotentiating reconstituted influenza virosomes and vaccines containing them | |
| US5149529A (en) | Compositions and treatment for herpes simplex | |
| Babai et al. | A novel influenza subunit vaccine composed of liposome-encapsulated haemagglutinin/neuraminidase and IL-2 or GM-CSF. I. Vaccine characterization and efficacy studies in mice | |
| AU689505B2 (en) | Protein- or peptide-cochleate vaccines and methods of immunizing using the same | |
| JP2005525992A (ja) | 生物学的物質を充填した小胞の調製法およびそれらの様々な使用 | |
| HU220136B (hu) | Eljárás liposzómákat tartalmazó vakcinakészítmény előállítására | |
| JPH04210925A (ja) | 鼻腔内または吸入投与用ワクチン製剤およびその製造方法 | |
| WO1993017702A1 (fr) | Vaccin oral | |
| CA3172986A1 (en) | Immunogenic composition comprising an antigenic moiety and a liposomal formulation, method of producing the composition, the composition for use as a medicament, in particular for use as a vaccin | |
| JP4638880B2 (ja) | アルキルホスファチジルコリン配合ワクチン組成物 | |
| TWI457145B (zh) | 以被包封於微脂粒內之蒂卡琳素（ｓｔｉｃｈｏｌｙｓｉｎ）為基礎的疫苗組成物 | |
| Gregoriadis | Liposomes as immunological adjuvants for peptide and protein antigens | |
| KR20050026681A (ko) | 서방성 미립구 형태의 ｉｌ-12 면역증강제를 포함하는백신 조성물 | |
| JP4480267B2 (ja) | ＨＢｓＡｇ粒子を介する免疫原性分子の送達 | |
| WO2003000232A2 (en) | Method for preparation of vesicles loaded with immunostimulator y oligodeoxynucleotides | |
| Gould-Fogerite et al. | Cochleate delivery vehicles: applications in vaccine delivery | |
| US7029680B1 (en) | Delivery of immunogenic molecules vis HBsAg particles | |
| Thibodeau | Immunosome technology to improve antigen presentation for efficient and safe viral vaccines | |
| GREGORIADIS | 1. LIPOSOMES AS IMMUNOLOGICAL ADJUVANTS | |
| Kersten et al. | Antigen Carriers: A Success Determining Factor for Subunit Vaccines? | |
| GREGORIADIS | ADJUVANTS FOR PEPTIDE AND PROTEIN | |
| JP2004161781A (ja) | 経口ワクチン | |
| Wijburg et al. | Liposomes as Systemic and Mucosal Delivery Vehicles |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FGA | Letters patent sealed or granted (standard patent) |